INNOVIMMUNE BIOTHERAPEUTICS HOLDING, LLC

Biotech · Private

Oral small-molecule MIF inhibitor (INV-88) for rheumatoid arthritis

Grants
$2.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis$995,900
Federal grantDepartment of Health and Human Services · Phase II · Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis$995,900
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2404ARTEMIS BIOTECHNOLOGIES LLC——
2405MARK THERAPEUTICS, INC.——
2406ONCOBLAZE LLC——
2407INNOVIMMUNE BIOTHERAPEUTICS HOLDING, LLC——
2408FLIK THERAPEUTICS, INC.——
2409AXENT BIOSCIENCES INC.——
2410CELLGRO TECHNOLOGIES, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.